Clinical Trial Update: A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer [Phase 2]

View source ↗

Summary

This source describes a single-center Phase II study evaluating the efficacy and safety of SCRT+CAPOX+serplulimab+bevacizumab for microsatellite-stable locally …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Serplulimab (serplulimab)

Snippet

Sponsor: First Affiliated Hospital of Wenzhou Medical University | Conditions: Locally Advanced Rectal Cancer (LARC) | Phase 2 | Status: RECRUITING